How do Selank and Semax differ chemically for identity verification?
Selank and Semax are both short synthetic peptides, but for analytical purposes they must be treated as separate entities with independent identity criteria. Semax is a heptapeptide derived from an ACTH(4-7) fragment extended with a Pro-Gly-Pro motif, while Selank is a heptapeptide based on a tuftsin-related sequence with its own Pro-Gly-Pro stabilising addition. Because their amino-acid compositions and sequences differ, their theoretical monoisotopic and average molecular masses differ, and this is the primary anchor for mass-spectrometry identity confirmation. An analytical laboratory should begin by calculating the expected average mass from the stated sequence and comparing it against the deconvoluted mass reported on the COA. A match within instrument tolerance (typically a few tenths of a Dalton for high-resolution instruments, or +/-1 Da for unit-resolution electrospray) supports identity; a systematic offset can indicate a residue substitution, an unexpected modification, or a mislabelled vial. These two peptides recur together across published pharmacology literature, including comparative studies of their carboxypeptidase activity in rat nervous tissue and enkephalin-degrading enzyme interactions in human serum, which underscores why laboratories routinely need to distinguish them analytically rather than assume equivalence. When a single supplier lists both, the documentation for each lot should carry its own sequence string, its own calculated mass and its own measured mass — never a shared or generic figure. Requiring peptide-specific identity data is the simplest guard against cross-labelling errors in a mixed catalogue.
What HPLC parameters establish chromatographic purity?
Reversed-phase high-performance liquid chromatography (RP-HPLC) is the workhorse for assessing the chromatographic purity of both Selank and Semax. A defensible method report should specify the stationary phase (commonly a C18 column), particle and pore size, column dimensions, mobile-phase composition (typically water and acetonitrile with an acidic modifier such as trifluoroacetic acid), the gradient programme, flow rate, column temperature and detection wavelength. Peptides with limited aromatic content are usually monitored in the low-UV region around 210-220 nm, where the peptide bond absorbs, rather than at 280 nm. Purity is reported as the percentage of the total integrated peak area attributable to the main peak, and the acceptance threshold should be stated explicitly on the COA (for example, main-peak area >=98 per cent). Equally important is that the report shows the actual chromatogram, not merely a number, so that the reviewer can judge baseline quality, peak symmetry, resolution from adjacent impurity peaks and whether integration was performed sensibly. Because Selank and Semax elute under different retention conditions, a single generic method may not resolve the related substances of both equally well; method suitability should be demonstrated per peptide. System-suitability data — such as theoretical plate count, tailing factor and injection repeatability — strengthen confidence that the reported purity figure is reproducible rather than a one-off measurement. Where two peptides are supplied together in a research programme, harmonising the reporting format across both makes cross-lot comparison far more reliable.
How does mass spectrometry confirm identity beyond retention time?
Retention time alone cannot confirm identity, because unrelated species can co-elute. Electrospray ionisation mass spectrometry (ESI-MS) provides the orthogonal evidence by measuring molecular weight directly. For short peptides such as Selank and Semax, ESI typically generates singly and doubly charged ions from which the neutral monoisotopic or average mass is calculated. The COA should present the observed mass and state how closely it matches the theoretical value derived from the declared sequence. For more rigorous identity confirmation, tandem mass spectrometry (MS/MS) fragments the precursor ion into b- and y-series fragments that map the amino-acid sequence, allowing a laboratory to distinguish, for instance, a correct heptapeptide from a deletion or substitution variant of identical nominal mass. This orthogonality — chromatographic behaviour plus mass and, ideally, fragmentation — is what separates a robust identity claim from an assumption. Published work using both peptides, including receptor-site and connectomic studies, treats each as a defined molecular entity, which is only meaningful if the material studied was verified to the stated structure. Buyers evaluating Australian-supplied research material should therefore expect the MS section of a COA to name the ionisation mode, the observed charge states or deconvoluted mass, and the mass error. A COA that reports HPLC purity but omits any mass-spectrometric identity data leaves the single most important question — is this actually the peptide named on the label — unanswered.
Which supporting assays complete a lot-release package?
Purity and identity are necessary but not sufficient for a complete lot-release dossier. Several supporting assays quantify what the primary UV chromatogram cannot see. Net peptide content (or peptide content assay) corrects the gross vial mass for non-peptide components, because a lyophilised powder also contains bound water, residual counterions and salts; the true peptide fraction is often well below 100 per cent of the weighed mass. Karl Fischer titration determines water content, which is relevant to both mass accounting and storage stability. Counterion analysis — commonly for trifluoroacetate when TFA is used in synthesis and purification — matters because residual TFA contributes to weighed mass and can interfere with certain downstream applications; ion chromatography or a dedicated counterion assay quantifies it. Amino-acid analysis offers an independent route to peptide content and compositional confirmation. Related-substance or impurity profiling characterises the minor peaks flanking the main peak, distinguishing benign process impurities from degradation products. For microbiological suitability in some research contexts, endotoxin testing may also be included. When two peptides such as Selank and Semax are procured together, applying the same panel of supporting assays to both — and recording each result against a pre-defined acceptance criterion — produces comparable, auditable documentation. The absence of net-peptide-content data is a common gap: without it, a stated concentration in a downstream experiment cannot be reconciled with the actual peptide mass delivered.
What stability and storage documentation should accompany the material?
Short peptides are subject to physical and chemical degradation pathways that analytical documentation should anticipate. Common concerns include hydrolysis, oxidation of susceptible residues, aggregation and, for lyophilised powders, moisture uptake that accelerates decomposition. A thorough supplier record notes the lyophilisation state, recommended storage temperature for the sealed powder, and guidance on protecting material from repeated temperature cycling. Cold-chain considerations are particularly relevant when material is dispatched across Australian distances, so shipping documentation ideally records the conditions under which the peptide travelled. For reconstituted solutions, stability is generally shorter than for the dry powder, and any solution-stability data provided should state the solvent system, storage temperature and the analytical method used to monitor purity over time — typically re-running RP-HPLC to detect the emergence of degradation peaks. Buyers should look for a stated retest or re-evaluation interval rather than an open-ended shelf claim, and for evidence that the vendor re-characterises retained samples. Because Selank and Semax differ in sequence, their degradation susceptibilities are not identical, so stability documentation should again be peptide-specific rather than a single generic statement covering the whole catalogue. Requesting the analytical method behind any stability claim — not merely the claim itself — allows a receiving laboratory to reproduce the assessment and to set its own retest schedule aligned to its storage conditions. None of these parameters speak to biological activity; they concern only the physicochemical integrity of the reference material.
How should an Australian laboratory audit vendor documentation before purchase?
Before acquiring Selank or Semax for research in Australia, a laboratory can apply a structured documentation audit that turns 'buy' intent into an evidence-based procurement decision. First, confirm the COA is lot-specific: it should carry a batch or lot number, a manufacture or test date, and results tied to that exact lot rather than a representative or historical certificate. Second, verify that identity and purity data are present and peptide-specific — a named sequence, a calculated mass, a measured mass with error, a labelled HPLC chromatogram and a stated purity threshold. Third, check that supporting assays (net peptide content, water content, counterion, related substances) are quantified against explicit acceptance criteria, not merely listed as 'conforms'. Fourth, review the analytical methods themselves: instrument type, column, mobile phase and detection conditions should be transparent enough to be reproduced or independently verified. Fifth, examine traceability — whether the vendor links each shipment to its underlying analytical records and retains samples for re-testing. Finally, align the received documentation with your own internal quality-management expectations so that incoming material is logged, inspected and accepted against pre-defined rules. This disciplined approach is consistent with how published pharmacology studies treat both peptides as defined entities, and it protects the integrity of downstream research. Throughout, the focus remains strictly analytical and research-use: documentation quality, identity and purity — never therapeutic use, benefit or human application.
Frequently asked questions
Are Selank and Semax the same molecule?
No. They are two distinct synthetic heptapeptides with different sequences and molecular masses. Each requires its own identity and purity documentation, and a certificate of analysis valid for one is not valid for the other. Always confirm the sequence and measured mass on a peptide-specific COA.
What HPLC purity threshold should a COA state?
The COA should state an explicit numerical acceptance criterion, commonly a main-peak area of at least 98 per cent by RP-HPLC, and include the actual chromatogram. A number without a chromatogram, method conditions and detection wavelength is difficult to verify or reproduce independently.
Why is mass spectrometry needed if HPLC already shows purity?
HPLC measures chromatographic purity but not molecular identity, since unrelated species can co-elute. ESI mass spectrometry confirms molecular weight against the theoretical value, and tandem MS can map the sequence. The two techniques are orthogonal and together provide robust identity confirmation.
What is net peptide content and why does it matter?
Net peptide content is the fraction of the weighed powder that is actually peptide, after correcting for water, counterions and salts. Without it, a stated concentration in a downstream experiment cannot be reconciled with the true peptide mass, so it is a key part of any complete lot-release package.
What documentation supports stability for shipped material?
Look for the lyophilisation state, recommended storage temperature, cold-chain shipping records, and — for solutions — the solvent, temperature and HPLC method used to monitor purity over time. A stated retest interval is preferable to an open-ended shelf claim, and stability data should be peptide-specific.
References
- DOI:10.1023/a:1011373002885 — Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum — Russian Journal of Bioorganic Chemistry — 2001
- DOI:10.1134/s1819712416010141 — The activities of basic carboxypeptidases in the nervous system of rats during exercise stress and in response to semax and selank — Neurochemical Journal — 2016
- DOI:10.31857/s1027813323020176 — Common and Specific Effects of Selank, Noopept, and Semax to Glycine Site of the NMDA Receptor in BALB/c and C57Bl/6 Mice Brain — Нейrochemistry — 2023
- DOI:10.1134/s001249662001007x — Functional Connectomic Approach to Studying Selank and Semax Effects — Doklady Biological Sciences — 2020
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
